Aimei Health Technology II, the second special purpose acquisition company (SPAC) formed by China-based investors targeting small-cap health tech, announced on Monday that it has filed with the Securities and Exchange Commission (SEC) to raise up to $60 million through an initial public offering (IPO).
The company intends to offer 6.0 million units at $10 per unit, with each unit comprising one share of common stock and one right to receive one-seventh (1/7) of a share of common stock following a de-SPAC transaction. Aimei Health Technology II is headquartered in New York, NY, but its sponsor is based in mainland China, and its CEO is located in Hong Kong.
The SPAC’s leadership includes CEO, CFO, and Director Heung Ming Wong. Wong currently serves as the CFO of Aimei Health Technology (AFJK), a SPAC that raised $60 million in December 2023, and which has a pending merger agreement with China-based hydrogen producer, United Hydrogen Global. Mr. Wong also holds board positions at several publicly-traded companies and was previously the CFO of Meten EdtechX Education Group.
Aimei Health Technology II plans to focus on identifying small-cap healthcare innovation companies for acquisition based in North America, Europe, or the Asia Pacific region (including China). Target industries include biopharmaceutical, medical technology/medical device, and diagnostics companies. The company was founded in 2024 and plans to list its units on the Nasdaq under the symbol AHJKU. A.G.P. will serve as the sole bookrunner for the deal, although a pricing date has not yet been determined.
